加拿大Angiotech www.angiotech.com 
AngioTech是加拿大的上市公司，主要业务为制药和医疗器械，总部在温哥华，是由几个著名外科医生创办的，也是医生把技术和专利转化成产品的成功例子。该公司成立以来，业务增长非常迅速，目前分别在欧洲的丹麦、美国的芝加哥和加州设有分支机构，该公司发明的“血管支架”、“手术缝合针线”等医疗产品技术非常先进，可以说改变了外科手术的潮流，一旦这些新产品上市，该公司的业务将以几何倍数增长。
Angiotech是比较年轻的特种药物和医疗设备公司，为医疗器件植入、外科手术干预和急性损伤相关疾病或并发症提供创新的治疗解决方案。

这间加拿大公司成立于1992年，作为共同创始人之一的William Hunter博士（现为CEO）当时还是卑斯大学的医科学生。Angiotech同各所大学和业界结成战略联盟，为其产品的商品化开辟渠道。加拿大政府的国家研究委员会有工业研究协助计划（NRC-IRAP），对于帮助该公司将科学理念转化为可应用的治疗解决方案也起到重要作用。

最初的开拓性开发项目之一是将紫杉醇这种药物输送到疾病部位以抑制血管生成的技术；血管生成会促进肿瘤、关节炎和其它慢性病的发展。紫杉醇经过加工用在TAXUS®冠状动脉支架中，由Boston Scientific Corporation营销和分销，已植入世界各地400多万病人的体内。

“加拿大政府通过NRC-IRAP等计划支持私营企业的研究工作，支持我们的创新文化，起到极其重要的作用，”Hunter博士说。

Angiotech [www.angiotech.com] 是加拿大在生命科学界占领先地位的又一个极好的范例。

补充资料

Angiotech在世界各地有1,300多名尽忠职守的员工。在加拿大，该企业的温哥华总办事处有近100名员工。
Angiotech目前有250多项美国专利和230多项美国专利待批申请。该公司的技术范围广泛，包括控制出血的止血钳和便于接通动脉的人工血管。
Angiotech是上市公司，其股票在多伦多证券交易所和纳斯达克买卖。

Angiotech is a global specialty pharmaceutical and medical device company that discovers, develops, and markets innovative technologies and medical products primarily for local diseases or for complications associated with medical device implants, surgical interventions and acute injury. We are listed on both the TSX and NASDAQ stock exchanges (TSX: ANP, NASDAQ: ANPI). The company's initial lead product, the TAXUS® drug-eluting coronary stent - which was co-developed and is now sold by Boston Scientific Corporation - is implanted in over four million patients worldwide.

We develop our products using a proprietary and systematic discovery approach. We use our drug screening capabilities to identify new uses for known pharmaceutical compounds. We look for compounds that address the underlying biological causes of conditions that can occur concurrently with medical device implantation, surgery or acute trauma. Once appropriate drugs have been identified, we formulate the drug, or combination of drugs, with our portfolio of biomaterials and drug delivery technologies to develop a novel drug-eluting medical device or surgical implant.

We have patent protected our technology and many of our products and potential product candidates, and our portfolio of intellectual property developed, licensed or acquired includes over 250 issued U.S. patents and 230 pending U.S. patent applications as of December 2007.

Following the acquisition of American Medical Instruments Holdings, Inc. in 2006, Angiotech expanded beyond its strong R&D capabilities to encompass the manufacturing and marketing of a wide range of single use, specialty medical devices, focused on interventional, surgical and OEM markets. Angiotech is currently working to develop a portfolio of next-generation products including its innovative Quill™ SRS, which is a bidirectional, barbed wound-closure device. Today, Angiotech has several specialized direct sales and distribution organizations in the United States and the European Union, as well as significant manufacturing capabilities.

At Angiotech, we are redefining success by striving to create novel medical solutions that elevate the standard of care and improve people's lives.